Wednesday, June 12
3:00-4:00 p.m. ET
Advance registration required

Tomorrow, Drew Weissman, M.D., Ph.D., a world-renowned physician, and researcher at Penn Medicine, will give a talk on nucleoside modified mRNA-LNP therapeutics in cancer research, as part of the NCI DCP IIG. In 2023, Dr. Weissman, along with Dr. Katalin Kariko, received the Nobel Prize in Physiology for mRNA vaccine discoveries that led to effective COVID vaccines.

Learn more about the seminar.

Tuesday, June 18
3:00-4:00 p.m. ET
Advance registration required

Join us to hear Paola Alberti, M.D., Ph.D., from the School of Medicine and Surgery at University of Milano-Bicocca, discuss methods for studying chemotherapy-induced peripheral neuropathy (CIPN) in preclinical studies and building collaborative translational teams. Ellen M. Lavoie Smith, Ph.D., M.S.N., R.N., AOCN^®, FAAN, from the University of Alabama at Birmingham School of Nursing, will then address methods and techniques for assessing CIPN in clinical trials.

Learn more about the webinar series.

NCI’s Cancer Moonshot^SM Tolerability Consortium is developing new ways to analyze clinical- and patient-reported data to better understand tolerability of cancer treatment and the patient experience. In this blog, learn about the consortium’s four funded interdisciplinary research teams that include physicians, biostatisticians, data scientists, investigators with patient reported outcome measurement expertise, cancer clinical trialists, and patient advocates.

Read the Cancer Prevention Science Blog.

Results of an NCI Community Oncology Research Program (NCORP) study about peripheral neuropathy among Black women being treated for breast cancer were presented at the ASCO Annual Meeting and simultaneously published in the Journal of Clinical Oncology (Schneider BP et al. J Clin Oncol. May 2024).
The study represented the first NCI-cooperative group trial to focus accrual entirely on a Black patient population with the goal of addressing clinically relevant disparate outcomes between Black and White women receiving taxane-based chemotherapy.

Listen to ASCO's podcast about the study.

Read the paper.

Tuesday, June 25 – Thursday, June 27
Boston, MA
Advance registration required

Last day to register! The American Cancer Society, NCI, and Cancer Research UK are launching their first annual conference on prevention research that aims to create a multidisciplinary cancer prevention research community, spark new collaborations and ideas, and advance cancer prevention.

View NCI Director, Dr. W_Kimryn_Rathmell's welcome video.

Registration deadline: June 11

For more information, including meeting agenda, speakers, and hotel, visit the Cancer Prevention Research Conference event website.

The NCI Division of Cancer Prevention has issued a call for nominations to feature early career scientists conducting research within the mission of the Division.

Selected investigators will be featured on DCP’s website and social media and will be invited to present their research to the broad NCI community through the DCP Early Career Scientist Spotlight Research Seminar Series. The overall goal is to increase visibility and provide recognition to early career scientists conducting research within the areas supported by DCP.

Nominations are due by June 30, 2024.

Learn more about this opportunity.

Monday, October 28- Wednesday, October 30
Poster Abstract Submission Deadline: August 15

The TACPAD meeting aims to: foster the exchange of ideas and create collaborative interactions among leading cancer prevention researchers, highlight new and emerging trends in immunoprevention and chemoprevention, and inform the research community of the significant NCI resources available to promote prevention agent development and rapid translation to clinical trials and to engage cancer researchers with novel prevention concepts.

Learn more about TACPAD.